Related Experiment Video
Updated: Jul 4, 2026

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice
Published on: December 8, 2023
Primary antifungal prophylaxis in hematopoietic stem cell transplant recipients: clinical implications of recent
1Division of Infectious Diseases, Oregon Health and Science University, Portland, Oregon 97239, USA. marrki@ohsu.edu
Purpose Of Review:
Infectious complications after hematopoietic stem cell transplant, especially those caused by fungi, contribute to poor outcomes. Availability of new antifungal drugs has led to creative attempts to prevent infections caused by both yeasts and molds with new antifungal prophylaxis strategies; these studies will be reviewed.
Recent Findings:
Trials evaluating mold-active azoles, posaconazole and voriconazole, demonstrate that invasive aspergillosis infections can be prevented by prophylactic therapy in patients with hematologic malignancies and after allogeneic hematopoietic stem cell transplant. However, issues arise regarding appropriate dosing and levels, drug interactions, and the importance of breakthrough infections caused by organisms that demonstrate microbiologic resistance. Other recent studies evaluating efficacy and safety of aerosolized lipid formulations of amphotericin B demonstrate promise with directed delivery to the lungs; more long-term follow-up safety information is needed to be assured that this strategy is safe late after allogeneic hematopoietic stem cell transplant, in the setting of acute and chronic graft vs. host disease.
Summary:
Clinicians should consider using new mold-active azole drugs for prophylaxis instead of fluconazole in allogeneic hematopoietic stem cell transplant recipients that have high risks due to prolonged neutropenia and severe graft vs. host disease. More investigations are needed to support other preventive strategies that utilize diagnostic tests and aerosolized delivery of amphotericin B formulations.
Insights
New mold-active azole antifungal drugs show promise in preventing invasive fungal infections in hematopoietic stem cell transplant patients. Further research is needed for aerosolized amphotericin B and diagnostic strategies.
Area of Science:
- Hematology
- Infectious Diseases
- Pharmacology
Background:
- Fungal infections pose a significant risk for poor outcomes in hematopoietic stem cell transplant (HSCT) recipients.
- Prophylaxis strategies are evolving with the advent of new antifungal agents to combat yeast and mold infections.
Purpose of the Study:
- To review current antifungal prophylaxis strategies for HSCT recipients.
- To evaluate the efficacy and safety of new antifungal drugs in preventing fungal infections post-HSCT.
Main Methods:
- Review of clinical trials evaluating mold-active azoles (posaconazole, voriconazole).
- Assessment of studies on aerosolized lipid formulations of amphotericin B.
- Analysis of data on breakthrough infections and drug resistance.
Main Results:
- Mold-active azoles effectively prevent invasive aspergillosis in hematologic malignancy patients and after allogeneic HSCT.
- Challenges include optimal dosing, drug interactions, and managing resistant breakthrough infections.
- Aerosolized amphotericin B shows potential for lung-directed delivery, but long-term safety data is pending.
Conclusions:
- Mold-active azoles are recommended over fluconazole for prophylaxis in high-risk allogeneic HSCT recipients.
- Additional research is required for diagnostic tests and aerosolized antifungal delivery methods.
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Cryptococcal Meningitis
Regulation of Hematopoietic Stem Cells
Antifungal Agents

